Clinical trial
BMS-247550 in Treating Patients With Liver or Gallbladder Cancer
NCT00023946 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00023946 |
|---|---|
| Title | BMS-247550 in Treating Patients With Liver or Gallbladder Cancer |
| Official title | A Phase II Trial Of The Epothilone B Analog BMS-247550 (NSC 710428D) In Patients With Hepatobiliary Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Primary Cholangiocellular Carcinoma, Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder, Localized Extrahepatic Bile Duct Cancer, Localized Gallbladder Cancer, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer and 4 more |
| Intervention type | Drug, Other |
| Interventions | ixabepilone, laboratory biomarker analysis |
| Enrollment | 50 |
| Start date | Aug 1, 2001 |
| Primary completion | Jul 1, 2005 |
| Completion | Nov 1, 2009 |
| First posted | Jan 27, 2003 |
| Last update posted | May 14, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: